BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Castéra L, Sebastiani G, Le Bail B, de Lédinghen V, Couzigou P, Alberti A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. Journal of Hepatology 2010;52:191-8. [DOI: 10.1016/j.jhep.2009.11.008] [Cited by in Crossref: 139] [Cited by in F6Publishing: 121] [Article Influence: 11.6] [Reference Citation Analysis]
Number Citing Articles
1 AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus: HEPATITIS C VIRUS GUIDANCE PANEL. Hepatology 2015;62:932-54. [DOI: 10.1002/hep.27950] [Cited by in Crossref: 844] [Cited by in F6Publishing: 832] [Article Influence: 120.6] [Reference Citation Analysis]
2 Calès P, Boursier J, Lebigot J, de Ledinghen V, Aubé C, Hubert I, Oberti F. Liver fibrosis diagnosis by blood test and elastography in chronic hepatitis C: agreement or combination? Aliment Pharmacol Ther 2017;45:991-1003. [DOI: 10.1111/apt.13954] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
3 Sebastiani G, Halfon P, Castera L, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Bourliere M, Alberti A. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C: Combination algorithms for liver fibrosis in HCV. Alimentary Pharmacology & Therapeutics 2012;35:92-104. [DOI: 10.1111/j.1365-2036.2011.04897.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
4 Adams LA. Biomarkers of liver fibrosis. J Gastroenterol Hepatol. 2011;26:802-809. [PMID: 21198831 DOI: 10.1111/j.1440-1746.2010.06612.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 5.9] [Reference Citation Analysis]
5 Gümüşay O, Ozenirler S, Atak A, Sönmez C, Ozkan S, Tuncel AF, Yılmaz G, Akyol G. Diagnostic potential of serum direct markers and non-invasive fibrosis models in patients with chronic hepatitis B. Hepatol Res 2013;43:228-37. [PMID: 22734888 DOI: 10.1111/j.1872-034X.2012.01057.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
6 Salkic NN, Cickusic E, Jovanovic P, Denjagic MB, Iljazovic-Topcic S, Bevanda M, Ahmetagic S. Online combination algorithm for non-invasive assessment of chronic hepatitis B related liver fibrosis and cirrhosis in resource-limited settings. Eur J Intern Med. 2015;26:628-634. [PMID: 26194460 DOI: 10.1016/j.ejim.2015.07.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
7 Jung J, Loomba RR, Imajo K, Madamba E, Gandhi S, Bettencourt R, Singh S, Hernandez C, Valasek MA, Behling C, Richards L, Fowler K, Sirlin CB, Nakajima A, Loomba R. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut 2021;70:1946-53. [PMID: 33214165 DOI: 10.1136/gutjnl-2020-322976] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
8 Petta S, Wong VW, Cammà C, Hiriart JB, Wong GL, Vergniol J, Chan AW, Di Marco V, Merrouche W, Chan HL, Marra F, Le-Bail B, Arena U, Craxì A, de Ledinghen V. Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. Aliment Pharmacol Ther 2017;46:617-27. [PMID: 28752524 DOI: 10.1111/apt.14219] [Cited by in Crossref: 79] [Cited by in F6Publishing: 69] [Article Influence: 15.8] [Reference Citation Analysis]
9 Romero Gutiérrez M, del Campo Terrón S, Moreno Zamora A, Sánchez Ruano JJ, Artaza Varasa T, Bárcena Marugán R. Does low-dose prolonged steroid therapy affect the natural history of chronic hepatitis C?: Effect of Low-Dose Corticoids On Hepatitis C. J Med Virol 2014;86:758-64. [DOI: 10.1002/jmv.23889] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
10 Kosick HM, Keyrouz A, Adeyi O, Sebastiani G, Patel K. A Stepwise Algorithmic Approach and External Validation Study for Noninvasive Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2021. [PMID: 33389416 DOI: 10.1007/s10620-020-06748-8] [Reference Citation Analysis]
11 Duarte-rojo A, Altamirano JT, Feld JJ. Noninvasive markers of fibrosis: key concepts for improving accuracy in daily clinical practice. Annals of Hepatology 2012;11:426-39. [DOI: 10.1016/s1665-2681(19)31456-5] [Cited by in Crossref: 31] [Article Influence: 3.1] [Reference Citation Analysis]
12 Omata M, Kanda T, Yu M, Yokosuka O, Lim S, Jafri W, Tateishi R, Hamid SS, Chuang W, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao J, Mccaughan GW. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012;6:409-35. [DOI: 10.1007/s12072-012-9342-y] [Cited by in Crossref: 114] [Cited by in F6Publishing: 128] [Article Influence: 11.4] [Reference Citation Analysis]
13 Yasar TK, Wagner M, Bane O, Besa C, Babb JS, Kannengiesser S, Fung M, Ehman RL, Taouli B. Interplatform reproducibility of liver and spleen stiffness measured with MR elastography. J Magn Reson Imaging. 2016;43:1064-1072. [PMID: 26469708 DOI: 10.1002/jmri.25077] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 6.7] [Reference Citation Analysis]
14 Suk KT, Kim DY, Sohn KM, Kim DJ. Biomarkers of liver fibrosis. Adv Clin Chem 2013;62:33-122. [PMID: 24772665 DOI: 10.1016/b978-0-12-800096-0.00002-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
15 Karanjia RN, Crossey MME, Cox IJ, Fye HKS, Njie R, Goldin RD, Taylor-Robinson SD. Hepatic steatosis and fibrosis: Non-invasive assessment. World J Gastroenterol 2016; 22(45): 9880-9897 [PMID: 28018096 DOI: 10.3748/wjg.v22.i45.9880] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
16 Lei B, Liu Y, Dong C, Chen X, Zhang X, Diao X, Yang G, Liu J, Yao S, Li H, Yuan J, Li S, Le X, Lin Y, Zeng W. Assessment of liver fibrosis in chronic hepatitis B via multimodal data. Neurocomputing 2017;253:169-76. [DOI: 10.1016/j.neucom.2016.09.128] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
17 European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63:199-236. [PMID: 25911336 DOI: 10.1016/j.jhep.2015.03.025] [Cited by in Crossref: 814] [Cited by in F6Publishing: 766] [Article Influence: 116.3] [Reference Citation Analysis]
18 Castera L. Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Int. 2011;5:625-634. [PMID: 21484142 DOI: 10.1007/s12072-010-9240-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
19 Zeng DW, Dong J, Liu YR, Jiang JJ, Zhu YY. Noninvasive models for assessment of liver fibrosis in patients with chronic hepatitis B virus infection. World J Gastroenterol 2016; 22(29): 6663-6672 [PMID: 27547009 DOI: 10.3748/wjg.v22.i29.6663] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
20 Menard M, Lecoindre A, Cadoré JL, Chevallier M, Pagnon A, Hernandez J, Leal RO, Hugonnard M, Miette V, Destro M, Rannou B, Benchekroun G, Lecoindre P. Use of serum biomarkers in staging of canine hepatic fibrosis. J Vet Diagn Invest 2019;31:665-73. [PMID: 31347473 DOI: 10.1177/1040638719866881] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Abd El-wahab EW, Ayoub HA, Shorbila AA, Mikheal A, Fadl M, Kotkat AM. Noninvasive biomarkers predict improvement in liver fibrosis after successful generic DAAs based therapy of chronic hepatitis C in Egypt. Clinical Epidemiology and Global Health 2020;8:1177-88. [DOI: 10.1016/j.cegh.2020.04.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Mehta SH, Kirk GD, Astemborski J, Sulkowski MS, Afdhal NH, Thomas DL. Stability of liver fibrosis among HCV-infected injection drug users. Antivir Ther 2012;17:813-21. [PMID: 22418880 DOI: 10.3851/IMP2085] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
23 Clark PJ, Patel K. Noninvasive tools to assess liver disease. Curr Opin Gastroenterol. 2011;27:210-216. [PMID: 21248634 DOI: 10.1097/MOG.0b013e328343e9a3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
24 Hansen JF, Christiansen KM, Staugaard B, Moessner BK, Lillevang S, Krag A, Christensen PB. Combining liver stiffness with hyaluronic acid provides superior prognostic performance in chronic hepatitis C. PLoS One 2019;14:e0212036. [PMID: 30742668 DOI: 10.1371/journal.pone.0212036] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
25 Moini M, Onofrio F, Hansen BE, Adeyi O, Khalili K, Patel K. Combination of FIB-4 with ultrasound surface nodularity or elastography as predictors of histologic advanced liver fibrosis in chronic liver disease. Sci Rep 2021;11:19275. [PMID: 34588540 DOI: 10.1038/s41598-021-98776-1] [Reference Citation Analysis]
26 de Oliveira AC, El-Bacha I, Vianna MV, Parise ER. Utility and limitations of APRI and FIB4 to predict staging in a cohort of nonselected outpatients with hepatitis C. Ann Hepatol. 2016;15:326-332. [PMID: 27049486 DOI: 10.5604/16652681.1198801] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
27 Friedrich-Rust M, Buggisch P, de Knegt RJ, Dries V, Shi Y, Matschenz K, Schneider MD, Herrmann E, Petersen J, Schulze F, Zeuzem S, Sarrazin C. Acoustic radiation force impulse imaging for non-invasive assessment of liver fibrosis in chronic hepatitis B. J Viral Hepat. 2013;20:240-247. [PMID: 23490368 DOI: 10.1111/j.1365-2893.2012.01646.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 4.5] [Reference Citation Analysis]
28 Castera L, Bedossa P. How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy? Liver Int. 2011;31 Suppl 1:13-17. [PMID: 21205132 DOI: 10.1111/j.1478-3231.2010.02380.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 4.0] [Reference Citation Analysis]
29 Sebastiani G, Gkouvatsos K, Plebani M. Non-invasive assessment of liver fibrosis: it is time for laboratory medicine. Clin Chem Lab Med. 2011;49:13-32. [PMID: 20961196 DOI: 10.1515/cclm.2011.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
30 European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60:392-420. [PMID: 24331294 DOI: 10.1016/j.jhep.2013.11.003] [Cited by in Crossref: 600] [Cited by in F6Publishing: 564] [Article Influence: 66.7] [Reference Citation Analysis]
31 Kemp W, Levy M, Weltman M, Lubel J. Australian Liver Association (ALA) expert consensus recommendations for the use of transient elastography in chronic viral hepatitis. J Gastroenterol Hepatol. 2015;30:453-462. [PMID: 25532416 DOI: 10.1111/jgh.12865] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
32 Jaffer OS, Lung PFC, Bosanac D, Shah A, Sidhu PS. Is ultrasound elastography of the liver ready to replace biopsy? A critical review of the current techniques. Ultrasound 2012;20:24-32. [DOI: 10.1258/ult.2011.011043] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
33 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu.; European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69:461-511. [PMID: 29650333 DOI: 10.1016/j.jhep.2018.03.026] [Cited by in Crossref: 905] [Cited by in F6Publishing: 751] [Article Influence: 226.3] [Reference Citation Analysis]
34 Loomba R, Adams LA. Advances in non-invasive assessment of hepatic fibrosis. Gut 2020;69:1343-52. [PMID: 32066623 DOI: 10.1136/gutjnl-2018-317593] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 19.5] [Reference Citation Analysis]
35 Frulio N, Trillaud H. Ultrasound elastography in liver. Diagn Interv Imaging. 2013;94:515-534. [PMID: 23623211 DOI: 10.1016/j.diii.2013.02.005] [Cited by in Crossref: 110] [Cited by in F6Publishing: 89] [Article Influence: 12.2] [Reference Citation Analysis]
36 Shaheen MA, Idrees M. Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease. World J Hepatol 2015; 7(3): 616-627 [PMID: 25848486 DOI: 10.4254/wjh.v7.i3.616] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
37 Papadopoulos N, Vasileiadi S, Papavdi M, Sveroni E, Antonakaki P, Dellaporta E, Koutli E, Michalea S, Manolakopoulos S, Koskinas J, Deutsch M. Liver fibrosis staging with combination of APRI and FIB-4 scoring systems in chronic hepatitis C as an alternative to transient elastography. Ann Gastroenterol 2019;32:498-503. [PMID: 31474797 DOI: 10.20524/aog.2019.0406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
38 Trivedi HD, Patwardhan VR, Malik R. Chronic hepatitis C infection — Noninvasive assessment of liver fibrosis in the era of direct acting antivirals. Digestive and Liver Disease 2019;51:183-9. [DOI: 10.1016/j.dld.2018.11.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
39 Boursier J, de Ledinghen V, Zarski JP, Fouchard-Hubert I, Gallois Y, Oberti F, Calès P. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology. 2012;55:58-67. [PMID: 21898504 DOI: 10.1002/hep.24654] [Cited by in Crossref: 81] [Cited by in F6Publishing: 71] [Article Influence: 8.1] [Reference Citation Analysis]
40 Heye T, Yang S, Bock M, Brost S, Weigand K, Longerich T, Kauczor H, Hosch W. MR relaxometry of the liver: significant elevation of T1 relaxation time in patients with liver cirrhosis. Eur Radiol 2012;22:1224-32. [DOI: 10.1007/s00330-012-2378-5] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 6.8] [Reference Citation Analysis]
41 Bracht T, Mölleken C, Ahrens M, Poschmann G, Schlosser A, Eisenacher M, Stühler K, Meyer HE, Schmiegel WH, Holmskov U, Sorensen GL, Sitek B. Evaluation of the biomarker candidate MFAP4 for non-invasive assessment of hepatic fibrosis in hepatitis C patients. J Transl Med 2016;14:201. [PMID: 27378383 DOI: 10.1186/s12967-016-0952-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
42 Schuppan D, Pinzani M. Anti-fibrotic therapy: lost in translation? J Hepatol 2012;56 Suppl 1:S66-74. [PMID: 22300467 DOI: 10.1016/S0168-8278(12)60008-7] [Cited by in Crossref: 73] [Cited by in F6Publishing: 37] [Article Influence: 7.3] [Reference Citation Analysis]
43 Capone F, Guerriero E, Sorice A, Maio P, Colonna G, Castello G, Costantini S. Characterization of metalloproteinases, oxidative status and inflammation levels in the different stages of fibrosis in HCV patients. Clin Biochem 2012;45:525-9. [PMID: 22366372 DOI: 10.1016/j.clinbiochem.2012.02.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
44 Martínez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology. 2011;53:325-335. [PMID: 21254180 DOI: 10.1002/hep.24013] [Cited by in Crossref: 272] [Cited by in F6Publishing: 248] [Article Influence: 22.7] [Reference Citation Analysis]
45 Cope R, Pickering A, Glowa T, Faulds S, Veldkamp P, Prasad R. Majority of HIV/HCV Patients Need to Switch Antiretroviral Therapy to Accommodate Direct Acting Antivirals. AIDS Patient Care STDS 2015;29:379-83. [PMID: 26066094 DOI: 10.1089/apc.2015.0004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
46 Schneider MD, Sarrazin C. Management of HCV-Associated Liver Cirrhosis. Visc Med 2016;32:96-104. [PMID: 27413726 DOI: 10.1159/000445330] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
47 Lee DH, Sung SU, Lee YK, Lim IH, Jang H, Joo SK, Park JH, Chang MS, So YH, Kim W; Innovative Target Exploration of NAFLD (ITEN) Consortium. A sequential approach using the age-adjusted fibrosis-4 index and vibration-controlled transient elastography to detect advanced fibrosis in Korean patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2022. [PMID: 35005800 DOI: 10.1111/apt.16766] [Reference Citation Analysis]
48 Guillaume M, Moal V, Delabaudiere C, Zuberbuhler F, Robic MA, Lannes A, Metivier S, Oberti F, Gourdy P, Fouchard-Hubert I, Selves J, Michalak S, Peron JM, Cales P, Bureau C, Boursier J. Direct comparison of the specialised blood fibrosis tests FibroMeterV2G and Enhanced Liver Fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres. Aliment Pharmacol Ther 2019;50:1214-22. [PMID: 31617224 DOI: 10.1111/apt.15529] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
49 Boursier J, Brochard C, Bertrais S, Michalak S, Gallois Y, Fouchard-Hubert I, Oberti F, Rousselet MC, Calès P. Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C. Aliment Pharmacol Ther. 2014;40:178-188. [PMID: 24889599 DOI: 10.1111/apt.12813] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
50 Liu Y, Dong CF, Yang G, Liu J, Yao S, Li HY, Yuan J, Li S, Le X, Lin Y, Zeng W, Lin H, Zhang X, Chen X. Optimal linear combination of ARFI, transient elastography and APRI for the assessment of fibrosis in chronic hepatitis B. Liver Int. 2015;35:816-825. [PMID: 24751289 DOI: 10.1111/liv.12564] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
51 Boursier J, Rousselet M, Aubé C, Calès P. Liver fibrosis in patients with non-alcoholic fatty liver disease: diagnostic options in clinical practice. Expert Opinion on Medical Diagnostics 2012;6:381-94. [DOI: 10.1517/17530059.2012.691878] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
52 Crisan D, Radu C, Lupsor M, Sparchez Z, Grigorescu MD, Grigorescu M. Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients. Hepat Mon. 2012;12:177-184. [PMID: 22550525 DOI: 10.5812/hepatmon.853] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
53 Zhang ZQ, Yang B, Zou H, Xiong L, Miao XY, Wen Y, Zhou JJ. ALBI/ST ratio versus FIB-4 and APRI as a predictor of posthepatectomy liver failure in hepatocellular carcinoma patients. Medicine (Baltimore) 2019;98:e15168. [PMID: 30985698 DOI: 10.1097/MD.0000000000015168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
54 Friedman SL. Hepatic Fibrosis. In: Schiff ER, Maddrey WC, Sorrell MF, editors. Schiff's Diseases of the Liver. Oxford: Wiley-Blackwell; 2011. pp. 295-315. [DOI: 10.1002/9781119950509.ch12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
55 Boursier J, de Ledinghen V, Zarski JP, Rousselet MC, Sturm N, Foucher J, Leroy V, Fouchard-Hubert I, Bertrais S, Gallois Y. A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol. 2011;106:1255-1263. [PMID: 21468012 DOI: 10.1038/ajg.2011.100] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 6.0] [Reference Citation Analysis]
56 Talal AH, Venuto CS, Younis I. Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment. Clin Pharmacol Drug Dev 2017;6:206-12. [PMID: 28263464 DOI: 10.1002/cpdd.336] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
57 Seto WK, Lee CF, Lai CL, Ip PP, Fong DY, Fung J, Wong DK, Yuen MF. A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B. PLoS One. 2011;6:e23077. [PMID: 21853071 DOI: 10.1371/journal.pone.0023077] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 4.5] [Reference Citation Analysis]
58 Fallatah HI. Noninvasive Biomarkers of Liver Fibrosis: An Overview. Advances in Hepatology 2014;2014:1-15. [DOI: 10.1155/2014/357287] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
59 Lesmana CR, Salim S, Hasan I, Sulaiman AS, Gani RA, Pakasi LS, Lesmana LA, Krisnuhoni E, Budihusodo U. Diagnostic accuracy of transient elastography (FibroScan) versus the aspartate transaminase to platelet ratio index in assessing liver fibrosis in chronic hepatitis B: the role in primary care setting. J Clin Pathol. 2011;64:916-920. [PMID: 21670074 DOI: 10.1136/jclinpath-2011-200044] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
60 Jung KS, Kim SU. Clinical applications of transient elastography. Clin Mol Hepatol 2012;18:163-73. [PMID: 22893866 DOI: 10.3350/cmh.2012.18.2.163] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 6.1] [Reference Citation Analysis]
61 Thandassery RB, Al Kaabi S, Soofi ME, Mohiuddin SA, John AK, Al Mohannadi M, Al Ejji K, Yakoob R, Derbala MF, Wani H, Sharma M, Al Dweik N, Butt MT, Kamel YM, Sultan K, Pasic F, Singh R. Mean Platelet Volume, Red Cell Distribution Width to Platelet Count Ratio, Globulin Platelet Index, and 16 Other Indirect Noninvasive Fibrosis Scores: How Much Do Routine Blood Tests Tell About Liver Fibrosis in Chronic Hepatitis C? Journal of Clinical Gastroenterology 2016;50:518-23. [DOI: 10.1097/mcg.0000000000000489] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
62 El-Sheikh RM, Mansy SS, Nessim IG, Hosni HN, El Hindawi A, Hassanein MH, AbdelFattah AS. Carbamoyl phosphate synthetase 1 (CPS1) as a prognostic marker in chronic hepatitis C infection. APMIS. 2019;127:93-105. [PMID: 30698308 DOI: 10.1111/apm.12917] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
63 Chromy D, Schwabl P, Bucsics T, Scheiner B, Strassl R, Mayer F, Aichelburg MC, Grabmeier-Pfistershammer K, Trauner M, Peck-Radosavljevic M, Reiberger T, Mandorfer M. Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients. Wien Klin Wochenschr 2018;130:105-14. [PMID: 28744597 DOI: 10.1007/s00508-017-1231-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
64 Moon HW, Park M, Hur M, Kim H, Choe WH, Yun YM. Usefulness of Enhanced Liver Fibrosis, Glycosylation Isomer of Mac-2 Binding Protein, Galectin-3, and Soluble Suppression of Tumorigenicity 2 for Assessing Liver Fibrosis in Chronic Liver Diseases. Ann Lab Med 2018;38:331-7. [PMID: 29611383 DOI: 10.3343/alm.2018.38.4.331] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
65 Liang XE, Dai L, Yang SL, Zhong CX, Peng J, Zhu YF, Chen YP, Hou JL. Combining routine markers improves the accuracy of transient elastography for hepatitis B cirrhosis detection. Dig Liver Dis. 2016;48:512-518. [PMID: 26965782 DOI: 10.1016/j.dld.2016.02.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
66 Pokorska-Śpiewak M, Dobrzeniecka A, Lipińska M, Tomasik A, Aniszewska M, Marczyńska M. Liver Fibrosis Evaluated With Transient Elastography in 35 Children With Chronic Hepatitis C Virus Infection. Pediatr Infect Dis J 2021;40:103-8. [PMID: 33021594 DOI: 10.1097/INF.0000000000002913] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
67 Friedrich-Rust M, Nierhoff J, Lupsor M, Sporea I, Fierbinteanu-Braticevici C, Strobel D, Takahashi H, Yoneda M, Suda T, Zeuzem S, Herrmann E. Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat. 2012;19:e212-e219. [PMID: 22239521 DOI: 10.1111/j.1365-2893.2011.01537.x] [Cited by in Crossref: 312] [Cited by in F6Publishing: 282] [Article Influence: 28.4] [Reference Citation Analysis]
68 Sebastiani G, Alberti A. How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C? J Viral Hepat. 2012;19 Suppl 1:18-32. [PMID: 22233410 DOI: 10.1111/j.1365-2893.2011.01518.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
69 Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142:1293-1302.e4. [PMID: 22537436 DOI: 10.1053/j.gastro.2012.02.017] [Cited by in Crossref: 411] [Cited by in F6Publishing: 368] [Article Influence: 41.1] [Reference Citation Analysis]
70 Patel K, Friedrich-Rust M, Lurie Y, Grigorescu M, Stanciu C, Lee CM, Schiff ER, Häussinger D, Manns MP, Gerken G, Colle I, Torbenson M, Pulkstenis E, Subramanian GM, McHutchison JG, Zeuzem S. FibroSURE and FibroScan® in relation to treatment response in chronic hepatitis C virus. World J Gastroenterol 2011; 17(41): 4581-4589 [PMID: 22147963 DOI: 10.3748/wjg.v17.i41.4581] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
71 Connolly JC, Lim JK. Non-invasive Fibrosis Assessment of Patients with Hepatitis C: Application of Society Guidelines to Clinical Practice. Curr Hepatology Rep 2019;18:249-58. [DOI: 10.1007/s11901-019-00471-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
72 Mendes LC, Stucchi RS, Vigani AG. Diagnosis and staging of fibrosis in patients with chronic hepatitis C: comparison and critical overview of current strategies. Hepat Med. 2018;10:13-22. [PMID: 29662329 DOI: 10.2147/hmer.s125234] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
73 Hur M, Park M, Moon HW, Choe WH, Lee CH. Comparison of Non-Invasive Clinical Algorithms for Liver Fibrosis in Patients With Chronic Hepatitis B to Reduce the Need for Liver Biopsy: Application of Enhanced Liver Fibrosis and Mac-2 Binding Protein Glycosylation Isomer. Ann Lab Med 2022;42:249-57. [PMID: 34635616 DOI: 10.3343/alm.2022.42.2.249] [Reference Citation Analysis]
74 Zarski JP, Sturm N, Guechot J, Paris A, Zafrani ES, Asselah T, Boisson RC, Bosson JL, Guyader D, Renversez JC, Bronowicki JP, Gelineau MC, Tran A, Trocme C, De Ledinghen V, Lasnier E, Poujol-Robert A, Ziegler F, Bourliere M, Voitot H, Larrey D, Rosenthal-Allieri MA, Fouchard Hubert I, Bailly F, Vaubourdolle M;  ANRS HCEP 23 Fibrostar Group. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol. 2012;56:55-62. [PMID: 21781944 DOI: 10.1016/j.jhep.2011.05.024] [Cited by in Crossref: 142] [Cited by in F6Publishing: 126] [Article Influence: 12.9] [Reference Citation Analysis]
75 Asrani SK. Incorporation of Noninvasive Measures of Liver Fibrosis Into Clinical Practice: Diagnosis and Prognosis. Clin Gastroenterol Hepatol 2015;13:2190-204. [PMID: 26226095 DOI: 10.1016/j.cgh.2015.07.030] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 4.9] [Reference Citation Analysis]
76 Kim MY, Jeong WK, Baik SK. Invasive and non-invasive diagnosis of cirrhosis and portal hypertension. World J Gastroenterol 2014; 20(15): 4300-4315 [PMID: 24764667 DOI: 10.3748/wjg.v20.i15.4300] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 58] [Article Influence: 8.1] [Reference Citation Analysis]
77 Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int. 2016;10:681-701. [PMID: 27229718 DOI: 10.1007/s12072-016-9736-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
78 Li Y, Cai Q, Zhang Y, Xie Q, Xu N, Jiang X, Li J, Li X, Zhang Z. Development of algorithms based on serum markers and transient elastography for detecting significant fibrosis and cirrhosis in chronic hepatitis B patients: Significant reduction in liver biopsy. Hepatol Res. 2016;46:1367-1379. [PMID: 26970087 DOI: 10.1111/hepr.12696] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
79 Canavan C, Eisenburg J, Meng L, Corey K, Hur C. Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK. Dig Dis Sci 2013;58:2691-704. [PMID: 23720196 DOI: 10.1007/s10620-013-2705-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
80 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245-264. [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023] [Cited by in Crossref: 847] [Cited by in F6Publishing: 805] [Article Influence: 77.0] [Reference Citation Analysis]
81 Crisan D, Radu C, Lupsor M, Sparchez Z, Grigorescu MD, Grigorescu M. Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients. Hepat Mon. 2012;12:177-184. [PMID: 22550525 DOI: 10.5812/hepatmon.5106] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
82 Liang XE, Zhong C, Huang L, Yang S, Zhu Y, Chen Y, Hou J. Optimization of hepatitis B cirrhosis detection by stepwise application of transient elastography and routine biomarkers: Detection of hepatitis B cirrhosis. Journal of Gastroenterology and Hepatology 2017;32:459-65. [DOI: 10.1111/jgh.13475] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
83 Lavaill L, Dussaucy A, Bardonnet K, Duraffourg N, Monnet E, Thévenot T, Davani S, Di Martino V; DEFI-HOSP Group. Automatic detection of cirrhosis in hospitalized patients: a pragmatic experience. Eur J Gastroenterol Hepatol 2016;28:74-81. [PMID: 26317562 DOI: 10.1097/MEG.0000000000000464] [Reference Citation Analysis]
84 Gaia S, Campion D, Evangelista A, Spandre M, Cosso L, Brunello F, Ciccone G, Bugianesi E, Rizzetto M. Non-invasive score system for fibrosis in chronic hepatitis: proposal for a model based on biochemical, FibroScan and ultrasound data. Liver Int 2015;35:2027-35. [PMID: 25495478 DOI: 10.1111/liv.12761] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
85 Cuesta-Sancho S, Márquez-Coello M, Illanes-Álvarez F, Márquez-Ruiz D, Arizcorreta A, Galán-Sánchez F, Montiel N, Rodriguez-Iglesias M, Girón-González JA. Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response. World J Hepatol 2022; 14(1): 62-79 [DOI: 10.4254/wjh.v14.i1.62] [Reference Citation Analysis]
86 . EASL Recommendations on Treatment of Hepatitis C 2014. Journal of Hepatology 2014;61:373-95. [DOI: 10.1016/j.jhep.2014.05.001] [Cited by in Crossref: 128] [Cited by in F6Publishing: 134] [Article Influence: 16.0] [Reference Citation Analysis]
87 European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66:153-194. [PMID: 27667367 DOI: 10.1016/j.jhep.2016.09.001] [Cited by in Crossref: 712] [Cited by in F6Publishing: 649] [Article Influence: 118.7] [Reference Citation Analysis]
88 Xiao G, Zhu F, Wang M, Zhang H, Ye D, Yang J, Jiang L, Liu C, Yan L, Qin R. Diagnostic accuracy of APRI and FIB-4 for predicting hepatitis B virus-related liver fibrosis accompanied with hepatocellular carcinoma. Digestive and Liver Disease 2016;48:1220-6. [DOI: 10.1016/j.dld.2016.06.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
89 Chen X, Wen H, Zhang X, Dong C, Lin H, Guo Y, Shan L, Yao S, Yang M, Le X, Liu Y. Development of a Simple Noninvasive Model to Predict Significant Fibrosis in Patients with Chronic Hepatitis B: Combination of Ultrasound Elastography, Serum Biomarkers, and Individual Characteristics. Clin Transl Gastroenterol. 2017;8:e84. [PMID: 28383564 DOI: 10.1038/ctg.2017.11] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
90 European Association for Study of Liver. Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237-264. [PMID: 25911335 DOI: 10.1016/j.jhep.2015.04.006] [Cited by in Crossref: 918] [Cited by in F6Publishing: 787] [Article Influence: 131.1] [Reference Citation Analysis]
91 Zeremski M, Martinez A. Liver Disease and Fibrosis Assessment in Substance Use-Related Disorders. Clin Pharmacol Drug Dev 2017;6:164-8. [PMID: 28263455 DOI: 10.1002/cpdd.312] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
92 Castera L. Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. Best Pract Res Clin Gastroenterol. 2011;25:291-303. [PMID: 21497746 DOI: 10.1016/j.bpg.2011.02.003] [Cited by in Crossref: 91] [Cited by in F6Publishing: 79] [Article Influence: 8.3] [Reference Citation Analysis]
93 Stefanescu H, Radu C, Procopet B, Lupsor-Platon M, Habic A, Tantau M, Grigorescu M. Non-invasive ménage à trois for the prediction of high-risk varices: stepwise algorithm using lok score, liver and spleen stiffness. Liver Int. 2015;35:317-325. [PMID: 25228102 DOI: 10.1111/liv.12687] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
94 Saad MF, Alenezi S, Asker H; Kuwait Hepatology Club. Expert opinion on the management of hepatitis C infection in Kuwait. Hepat Med. 2018;10:117-132. [PMID: 30319294 DOI: 10.2147/hmer.s154842] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
95 Pár A, Pár G. Non-invasive fibrosis assessment in chronic hepatitis C: aspartate-aminotransferase to platelet ratio index (APRI) and transient elastography (FibroScan). Orvosi Hetilap 2010;151:1951-5. [DOI: 10.1556/oh.2010.28978] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
96 Yamada H, Kondou H, Kimura T, Ikeda K, Tachibana M, Hasegawa Y, Kiyohara Y, Ueno T, Miyoshi Y, Mushiake S, Ozono K. Humoral immunity is involved in the development of pericentral fibrosis after pediatric live donor liver transplantation. Pediatr Transplant. 2012;16: 858-865. [PMID: 22931465 DOI: 10.1111/j.1399-3046.2012.01781.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
97 Cobbold JF, Patel D, Fitzpatrick JA, Patel N, Crossey MM, Abdalla MS, Goldin RD, Vennart W, Thomas HC, Taylor-Robinson SD. Accuracy and reliability of microbubble ultrasound measurements for the non-invasive assessment of hepatic fibrosis in chronic hepatitis C. Hepatol Res. 2012;42:515-522. [PMID: 22502745 DOI: 10.1111/j.1872-034x.2011.00948.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
98 Boursier J, Guillaume M, Leroy V, Irlès M, Roux M, Lannes A, Foucher J, Zuberbuhler F, Delabaudière C, Barthelon J, Michalak S, Hiriart JB, Peron JM, Gerster T, Le Bail B, Riou J, Hunault G, Merrouche W, Oberti F, Pelade L, Fouchard I, Bureau C, Calès P, de Ledinghen V. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD. J Hepatol. 2019;71:389-396. [PMID: 31102719 DOI: 10.1016/j.jhep.2019.04.020] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 15.3] [Reference Citation Analysis]
99 Sporea I, Şirli R, Popescu A, Bota S, Badea R, Lupşor M, Focşa M, Dănilă M. Is it better to use two elastographic methods for liver fibrosis assessment? World J Gastroenterol 2011; 17(33): 3824-3829 [PMID: 21987625 DOI: 10.3748/wjg.v17.i33.3824] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
100 Vermehren J, Vermehren A, Mueller A, Carlebach A, Lutz T, Gute P, Knecht G, Sarrazin C, Friedrich-Rust M, Forestier N, Poynard T, Zeuzem S, Herrmann E, Hofmann WP. Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers. BMC Gastroenterol 2012;12:27. [PMID: 22453133 DOI: 10.1186/1471-230X-12-27] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
101 Andrés-Otero MJ, De-Blas-Giral I, Puente-Lanzarote JJ, Serrano-Aulló T, Morandeira MJ, Lorente S, Lou-Bonafonte JM. Multiple approaches to assess fourteen non-invasive serum indexes for the diagnosis of liver fibrosis in chronic hepatitis C patients. Clin Biochem 2016;49:560-5. [PMID: 26968102 DOI: 10.1016/j.clinbiochem.2015.12.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
102 Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 56.5] [Reference Citation Analysis]
103 Crespo G, Forns X, Navasa M. [Serum markers of liver fibrosis in patients with chronic hepatitis C infection. Prognostic value of noninvasive markers of fibrosis in liver transplantation]. Gastroenterol Hepatol 2012;35 Suppl 2:17-22. [PMID: 23298655 DOI: 10.1016/S0210-5705(12)70045-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
104 Kohla MAS, Abbasy M, Abozeid M, El-Abd O, Ezzat S, Kohla S, Abdel-Rahman M. Assessment of liver fibrosis with acoustic radiation force impulse imaging versus liver histology in patients with chronic hepatitis C: a pilot study. Eur J Gastroenterol Hepatol 2017;29:951-5. [PMID: 28471822 DOI: 10.1097/MEG.0000000000000903] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
105 Carmona I, Cordero P, Ampuero J, Rojas A, Romero-Gómez M. Role of assessing liver fibrosis in management of chronic hepatitis C virus infection. Clin Microbiol Infect 2016;22:839-45. [PMID: 27677698 DOI: 10.1016/j.cmi.2016.09.017] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
106 Merchante N, López-Cortés LF, Delgado-Fernández M, Ríos-Villegas MJ, Márquez-Solero M, Merino D, Pasquau J, García-Figueras C, Martínez-Pérez MA, Omar M, Rivero A, Macías J, Mata R, Pineda JA; Grupo Andaluz para el Estudio de las Hepatitis Vıricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients. AIDS Patient Care STDS 2011;25:395-402. [PMID: 21688986 DOI: 10.1089/apc.2011.0109] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
107 Pár G, Trosits A, Pakodi F, Szabó I, Czimmer J, Illés A, Gódi S, Bajor J, Sarlós P, Kenyeres P, Miseta A, Vincze A, Pár A. [Transient elastography as a predictor of oesophageal varices in patients with liver cirrhosis]. Orv Hetil 2014;155:270-6. [PMID: 24509356 DOI: 10.1556/OH.2014.29824] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
108 Kang Q, Xu J, Luo H, Tan N, Chen H, Cheng R, Pan J, Han Y, Yang Y, Liu D, Xi H, Yu M, Xu X. Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication. J Viral Hepat 2021;28:1284-92. [PMID: 34105867 DOI: 10.1111/jvh.13558] [Reference Citation Analysis]
109 Pokorska-Śpiewak M, Kowalik-Mikołajewska B, Aniszewska M, Pluta M, Marczyńska M. Is liver biopsy still needed in children with chronic viral hepatitis? World J Gastroenterol 2015; 21(42): 12141-12149 [PMID: 26576098 DOI: 10.3748/wjg.v21.i42.12141] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
110 Bhogal H, Sterling RK. Staging of liver disease: which option is right for my patient? Infect Dis Clin North Am. 2012;26:849-861. [PMID: 23083819 DOI: 10.1016/j.idc.2012.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
111 Stasi C, Milani S. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness. World J Gastroenterol 2016; 22(4): 1711-1720 [PMID: 26819535 DOI: 10.3748/wjg.v22.i4.1711] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
112 Balabaud C, Bioulac-Sage P. Cirrhosis: what else? Gastroenterol Clin Biol. 2010;34:252-254. [PMID: 20537484 DOI: 10.1016/j.gcb.2010.03.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
113 Castera L, Winnock M, Pambrun E, Paradis V, Perez P, Loko MA, Asselineau J, Dabis F, Degos F, Salmon D. Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration. HIV Med. 2014;15:30-39. [PMID: 24007567 DOI: 10.1111/hiv.12082] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 4.9] [Reference Citation Analysis]
114 Cope R, Glowa T, Faulds S, McMahon D, Prasad R. Treating Hepatitis C in a Ryan White-Funded HIV Clinic: Has the Treatment Uptake Improved in the Interferon-Free Directly Active Antiviral Era? AIDS Patient Care STDS 2016;30:51-5. [PMID: 26744994 DOI: 10.1089/apc.2015.0222] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
115 Jiang H, Zheng T, Duan T, Chen J, Song B. Non-invasive in vivo Imaging Grading of Liver Fibrosis. J Clin Transl Hepatol. 2018;6:198-207. [PMID: 29951365 DOI: 10.14218/jcth.2017.00038] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
116 Schiavon LL, Narciso-Schiavon JL, Carvalho-Filho RJ. Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. World J Gastroenterol 2014; 20(11): 2854-2866 [PMID: 24659877 DOI: 10.3748/wjg.v20.i11.2854] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
117 Chen YP, Huang LW, Lin XY, Hu XM, Liang XE, Jiang RL. Alanine aminotransferase influencing performances of routine available tests detecting hepatitis B-related cirrhosis. J Viral Hepat 2020;27:826-36. [PMID: 32187804 DOI: 10.1111/jvh.13293] [Reference Citation Analysis]
118 Kanwal F, Kramer JR, Asch SM, Cao Y, Li L, El-Serag HB. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology. 2020;71:44-55. [PMID: 31222774 DOI: 10.1002/hep.30823] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 22.7] [Reference Citation Analysis]
119 Bruguera M, Esteban R, Forns X, Planas R, Quer JC, Solà R, Vergara M. Documento de posicionamiento de la Societat Catalana de Digestología: tratamiento triple de la hepatitis crónica C genotipo 1. Gastroenterología y Hepatología 2012;35:667-74. [DOI: 10.1016/j.gastrohep.2012.03.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
120 Valva P, Ríos DA, De Matteo E, Preciado MV. Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage. World J Gastroenterol 2016; 22(4): 1367-1381 [PMID: 26819506 DOI: 10.3748/wjg.v22.i4.1367] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
121 Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, Hige S, Sakamoto M, Kage M, Mizokami M, Narimatsu H. A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013;3:1065. [PMID: 23323209 DOI: 10.1038/srep01065] [Cited by in Crossref: 215] [Cited by in F6Publishing: 197] [Article Influence: 23.9] [Reference Citation Analysis]
122 Sebastiani G, Gkouvatsos K, Pantopoulos K. Chronic hepatitis C and liver fibrosis. World J Gastroenterol 2014; 20(32): 11033-11053 [PMID: 25170193 DOI: 10.3748/wjg.v20.i32.11033] [Cited by in CrossRef: 117] [Cited by in F6Publishing: 97] [Article Influence: 14.6] [Reference Citation Analysis]
123 Park SH, Bang CS, Kim DJ. Biomarkers in HCV Infection. Adv Clin Chem 2015;70:131-96. [PMID: 26231487 DOI: 10.1016/bs.acc.2015.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
124 Payen T, Palermo CF, Sastra SA, Chen H, Han Y, Olive KP, Konofagou EE. Elasticity mapping of murine abdominal organs in vivo using harmonic motion imaging (HMI). Phys Med Biol 2016;61:5741-54. [PMID: 27401609 DOI: 10.1088/0031-9155/61/15/5741] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]